Recombinant human BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag, low endotoxin, 100 µg

Background
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

Source
Recombinant Human BCMA, Llama IgG2b Fc Tag (BCA-H5259) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 54 (Accession # Q02223-1).
Predicted N-terminus: Met 1

Molecular Characterization
This protein carries a llama IgG2b Fc tag at the C-terminus.
The protein has a calculated MW of 33.7 kDa. The protein migrates as 40-47 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.01 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "IL-18-secreting multi-antigen targeting CAR T-cells eliminate antigen-low myeloma in an immunocompetent mouse model"
Ng, Rajagopalan, Kousa et al
Blood (2024)
(2) "CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy"
Ledergor, Fan, Wu et al
Blood Adv (2024)
(3) "Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma"
Munawar, Theuersbacher, Steinhardt et al
Haematologica (2024)
Showing 1-3 of 1299 papers.